Lindbrook Capital LLC Increases Holdings in Baxter International Inc. (NYSE:BAX)

Lindbrook Capital LLC raised its stake in Baxter International Inc. (NYSE:BAX) by 8.8% during the 4th quarter, HoldingsChannel reports. The firm owned 4,586 shares of the medical instruments supplier’s stock after acquiring an additional 372 shares during the quarter. Lindbrook Capital LLC’s holdings in Baxter International were worth $177,000 as of its most recent SEC filing.

Several other hedge funds also recently added to or reduced their stakes in the stock. Headinvest LLC acquired a new stake in shares of Baxter International in the third quarter valued at about $25,000. Bruce G. Allen Investments LLC purchased a new stake in shares of Baxter International during the fourth quarter valued at approximately $36,000. Turtle Creek Wealth Advisors LLC acquired a new position in shares of Baxter International during the fourth quarter worth $37,000. CKW Financial Group acquired a new stake in Baxter International during the 4th quarter valued at $43,000. Finally, BKM Wealth Management LLC purchased a new stake in Baxter International during the 4th quarter worth $44,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International Stock Performance

Shares of NYSE BAX opened at $40.40 on Tuesday. The company has a quick ratio of 1.04, a current ratio of 1.48 and a debt-to-equity ratio of 1.31. The firm’s 50-day moving average price is $41.80 and its two-hundred day moving average price is $38.46. Baxter International Inc. has a 52-week low of $31.01 and a 52-week high of $50.21. The stock has a market capitalization of $20.52 billion, a P/E ratio of 7.74, a P/E/G ratio of 2.12 and a beta of 0.62.

Baxter International (NYSE:BAX) last announced its quarterly earnings results on Thursday, February 8th. The medical instruments supplier reported $0.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.86 by $0.02. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.81 billion. Baxter International had a return on equity of 19.49% and a net margin of 17.77%. The business’s revenue was up 3.5% on a year-over-year basis. During the same quarter last year, the business posted $0.88 EPS. As a group, sell-side analysts forecast that Baxter International Inc. will post 2.89 earnings per share for the current year.

Baxter International Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, April 1st. Stockholders of record on Friday, March 1st were given a dividend of $0.29 per share. The ex-dividend date was Thursday, February 29th. This represents a $1.16 annualized dividend and a dividend yield of 2.87%. Baxter International’s dividend payout ratio is currently 22.22%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Barclays boosted their price objective on shares of Baxter International from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Monday, February 12th. Citigroup raised their price objective on Baxter International from $41.00 to $44.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. UBS Group cut their target price on Baxter International from $40.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 6th. StockNews.com raised shares of Baxter International from a “hold” rating to a “buy” rating in a research report on Friday, January 19th. Finally, Bank of America lifted their price target on shares of Baxter International from $42.00 to $45.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 5th. Seven investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $46.30.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.